Literature DB >> 12160144

Postoperative radiation therapy for medulloblastoma--high recurrence rate in the subfrontal region.

Li-Min Sun1, Shyh-An Yeh, Chong-Jong Wang, Eng-Yen Huang, Hui-Chun Chen, Hsuan-Chih Hsu, Steve P Lee.   

Abstract

PURPOSE: To investigate the treatment results and analyze the prognostic factors for patients with medulloblastoma (MB) treated by surgery and postoperative radiation therapy (RT). METHODS AND MATERIALS: Thirty-five patients of MB receiving surgery followed by RT from February 1986 to September 1999 were reviewed. Their median age was 12 years with a slight male predominance. Twenty-four (69%) patients had total resection of tumor. Most (86%) cases received craniospinal irradiation (CSI). Adequate dose (craniospinal dose > 30 Gy and posterior fossa dose > or = 50 Gy) was given in 26 (74%) patients.
RESULTS: The median survival duration was 48 months. The 5-year and 10-year overall survival rates were 63% and 40%, respectively. Univariate analysis revealed that stage, shunt surgery, RT dose, and protracted RT course were significant factors in predicting overall survival (OS), disease-free survival (DFS), and/or posterior fossa control (PFC). Multivariate analysis showed that RT dose affected OS and PFC independently, stage influenced OS and DFS, while protracted RT course impacted DFS. A total of 20 cases developed disease relapse. The median time to relapse was 18 months. The posterior fossa (10 cases) was the most common site of first failure, followed by the subfrontal lobe (7 cases), spine (6 cases), and other areas (4 cases).
CONCLUSION: Our results were compatible with others, except that more subfrontal relapses were found. Surgical resection followed by standard dose and adequate margin of CSI are recommended as the mainstays of treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12160144     DOI: 10.1023/a:1015865614640

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Subfrontal recurrence of medulloblastoma.

Authors:  J Donnal; E C Halperin; H S Friedman; O B Boyko
Journal:  AJNR Am J Neuroradiol       Date:  1992 Nov-Dec       Impact factor: 3.825

Review 2.  Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.

Authors:  F H Saran; P H Driever; C Thilmann; S Mose; P Wilson; G Sharpe; I A Adamietz; H D Böttcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-12-01       Impact factor: 7.038

Review 3.  Impact of radiation technique upon the outcome of treatment for medulloblastoma.

Authors:  E C Halperin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-08-01       Impact factor: 7.038

4.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

5.  Influence of a child's sex on medulloblastoma outcome.

Authors:  M D Weil; K Lamborn; M S Edwards; W M Wara
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

6.  Radiation for medulloblastoma adjusted to prevent recurrence to the cribriform plate region.

Authors:  B Jereb; S Krishnaswami; A Reid; J C Allen
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

7.  Adult medulloblastoma: prognostic factors and patterns of relapse.

Authors:  A W Chan; N J Tarbell; P M Black; D N Louis; M P Frosch; M Ancukiewicz; P Chapman; J S Loeffler
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

8.  Medulloblastoma: time-dose relationship based on a 30-year review.

Authors:  J O del Charco; T W Bolek; W M McCollough; B L Maria; A Kedar; R C Braylan; J P Mickle; J M Buatti; N P Mendenhall; R B Marcus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

9.  Medulloblastoma: experience of a single institution.

Authors:  J E Wolff; U Huettermann; J Ritter; R Straeter; D Palm; C Ruebe; K H Kraehling; H Jürgens
Journal:  Klin Padiatr       Date:  1998 Jul-Aug       Impact factor: 1.349

10.  Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?

Authors:  N Fukunaga-Johnson; J H Lee; H M Sandler; P Robertson; E McNeil; J W Goldwein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

View more
  11 in total

Review 1.  Subfrontal recurrence after cerebellar medulloblastoma resection without local relapse: case-based update.

Authors:  He Yue; Wang Ling; Ou Yibo; Wang Sheng; Tang Sicheng; Chen Jincao; Guo Dongsheng
Journal:  Childs Nerv Syst       Date:  2018-06-23       Impact factor: 1.475

2.  Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Authors:  Fadila Guessous; Yanzhi Yang; Elizabeth Johnson; Lukasz Marcinkiewicz; Matthew Smith; Ying Zhang; Alexander Kofman; David Schiff; James Christensen; Roger Abounader
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

Review 3.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

4.  SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42.

Authors:  Praveen Bhoopathi; Christopher S Gondi; Meena Gujrati; Dzung H Dinh; Sajani S Lakka
Journal:  Cell Signal       Date:  2011-07-23       Impact factor: 4.315

5.  Recurrence in childhood medulloblastoma.

Authors:  Monika Warmuth-Metz; Sophia Blashofer; André O von Bueren; Katja von Hoff; Brigitte Bison; Fabian Pohl; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski
Journal:  J Neurooncol       Date:  2010-11-11       Impact factor: 4.130

6.  Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.

Authors:  Arun Kumar Nalla; Swapna Asuthkar; Praveen Bhoopathi; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

7.  Patterns of Failure Following Multimodal Treatment for Medulloblastoma: Long-Term Follow-up Results at a Single Institution.

Authors:  Dong Soo Lee; Jaeho Cho; Se Hoon Kim; Dong-Seok Kim; Kyu Won Shim; Chuhl Joo Lyu; Jung Woo Han; Chang-Ok Suh
Journal:  Cancer Res Treat       Date:  2014-12-08       Impact factor: 4.679

8.  Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Authors:  Zhen-Yu Zhang; Jian Xu; Yong Ren; Kay Ka-Wai Li; Ho-Keung Ng; Ying Mao; Ping Zhong; Yu Yao; Liang-Fu Zhou
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

9.  Supratentorial metastasis of medulloblastoma in adults.

Authors:  Sushil Kumar; Amit Handa; Deepak K Jha; Ajay Choudhary
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep

10.  Isolated Supratentorial Intraventricular Recurrence of Medulloblastoma.

Authors:  Kingsley O Abode-Iyamah; Nolan Winslow; Oliver Flouty; Patricia Kirby
Journal:  J Korean Neurosurg Soc       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.